Is Mounjaro a Diabetes Drug — or a Weight-Loss Medicine?

The decision you're probably trying to make right now

Most people asking this question fall into one of two camps. Either they have been told Mounjaro is a diabetes drug and are wondering whether it's appropriate for weight loss, or they've heard about it for weight loss and are unsure whether it's really meant for them. Both concerns are reasonable, and both reflect the same underlying fact: Mounjaro arrived in UK clinical practice carrying a dual identity.

Tirzepatide was originally developed and trialled in diabetes, and you can read a full overview of Mounjaro's role in diabetes treatment if that context would help you. The UK diabetes licence came first. The weight-management licence (covering adults with obesity or excess weight alongside a health condition) followed as trial evidence from the SURMOUNT programme accumulated. By the time NICE published its appraisal of tirzepatide for weight management (TA1026, December 2024), the clinical case for both uses was well established. The NHS page on tirzepatide sets out both indications clearly.

So what matters for you? Whether you have type 2 diabetes, a weight-related condition, or both shapes which licence your prescriber works from. It also shapes how Mounjaro interacts with any other medication you take. That's the decision at the centre of this page, and it can only be resolved in a clinical conversation, not by the licence name alone. Our clinical team is made up of GPhC-registered Independent Prescribers who review exactly this kind of picture before any treatment is issued.

What the diabetes licence covers, and what it doesn't say about weight

Under its type 2 diabetes licence, Mounjaro is prescribed to improve blood-sugar control in adults whose glucose levels are not adequately managed by diet alone or alongside other diabetes medicines. It is not licensed for type 1 diabetes. The question of Mounjaro and type 1 diabetes is a separate clinical topic, and the short answer from current UK guidance is that the evidence base simply isn't there yet.

What the diabetes licence does not do is exclude weight loss as a benefit. Tirzepatide's mechanism (acting on two gut-hormone receptors simultaneously) produces meaningful appetite reduction alongside its blood-sugar effects. In clinical trials in adults with type 2 diabetes and obesity, participants lost significant body weight even under the diabetes-focused study design. That weight reduction is a recognised secondary benefit, not a side effect to be managed. But prescribing Mounjaro primarily to someone who does not have type 2 diabetes, under the diabetes licence, would be clinically inappropriate. The weight-management licence exists precisely to make the medicine available to people without diabetes who meet the BMI criteria.

If you have type 2 diabetes and are also hoping to lose weight, a prescriber may well find Mounjaro appropriate under either or both indications, and our dedicated page on using Mounjaro for type 2 diabetes covers how that works in practice. The question of how Mounjaro performs specifically in diabetes management is worth reading if that's your primary concern.

The weight-management licence: who it's for and what the evidence shows

For people without type 2 diabetes, the relevant licence is the weight-management one. Under NICE guidance TA1026, tirzepatide is recommended for adults with a BMI of 35 or above and at least one weight-related health condition, within an NHS specialist service, though the BMI threshold is 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Private prescribing, including through a service like nume's Mounjaro treatment, follows the licensed eligibility criteria from the SmPC rather than the NICE NHS thresholds.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20 to 21 percent at the 15mg dose over 72 weeks among adults with obesity who did not have diabetes. Those figures give some sense of scale, but they describe trial populations, not individual outcomes, and a prescriber reviewing your full medical history will be the one to judge what's realistic for you.

On the private route, there's no referral letter to organise, no waiting list, and no need to meet the stricter NHS cohort criteria. A consultation can be completed any morning before noon (handy if you're sorting admin before the school run) and a prescriber reviews it the same day. The treatment page sets out how that process works step by step.

Safety, contraindications, and who should not use Mounjaro

Regardless of which licence applies, Mounjaro carries the same safety profile. Common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and reduced appetite are typical, particularly in the early weeks of treatment or after a dose increase. These usually ease as the body adjusts. Severe or persistent stomach pain that spreads to the back warrants urgent medical attention, as the MHRA highlighted in its January 2026 Drug Safety Update on pancreatitis risk with GLP-1 class medicines, details of which appear on the MHRA Yellow Card site, which patients can also use to report any suspected side effects.

Mounjaro is not recommended for anyone who is pregnant, breastfeeding, or actively trying to conceive. It is not licensed for use in people under 18. Women using oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption, NHS England's guidance on weight-management injections covers this clearly.

A history of medullary thyroid carcinoma or certain other conditions requires a full discussion with a prescriber before Mounjaro is considered. This is not a medicine where self-assessment is sufficient. If you have questions about your specific situation, our support team can point you to the right clinical pathway. For a broader look at how Mounjaro fits into the UK weight-loss treatment landscape, the weight-loss treatment overview gives useful context. Questions about cost can be found on the Mounjaro prices page.